Barclays Maintains an 'Equalweight' Rating on Covance (CVD); Thoughts on Sanofi-Aventis Deal
Tweet Send to a Friend
Barclays maintains an 'Equalweight' rating on Covance Inc (NYSE: CVD), price target $41.
Barclays analyst says, "Covance delivered much needed ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst says, "Covance delivered much needed ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
